Roche Holding AG RHHBF
479.42 USD -25.63 (-5.08%)
Regular-session close
483.07 Day range 483.26
375.00 52-week range 514.08
- YTD
- +7.59%
- 1 year
- +26.83%
- Market cap
- 381.98B
- EPS (ttm)
- 20.35
- P/E ratio
- 23.56
- YTD return
- +7.59%
- 1-year return
- +26.83%
- Volume
- 4
- Avg volume
- 93
- Open
- 483.26
- Previous close
- 505.05
- Day's range
- 483.07 – 483.26
- 52-week range
- 375.00 – 514.08
No chart data for this range yet.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
RHHBY Secures FDA Approval for Breast Cancer Treatment
Roche Secures First U.S. Approval for New Breast-Cancer Pill
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
US FDA approves Roche's oral treatment for advanced breast cancer
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Roche: Valuation Leaves Limited Upside
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.
